{"id":5823,"date":"2010-03-10T17:18:15","date_gmt":"2010-03-10T22:18:15","guid":{"rendered":"http:\/\/asweetlife.org\/?p=5823"},"modified":"2015-12-27T15:44:29","modified_gmt":"2015-12-27T20:44:29","slug":"teplizumab-on-word-of-mouth","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=5823","title":{"rendered":"Teplizumab on Word of Mouth"},"content":{"rendered":"

\"\"<\/a>Great personal news: my piece in Popular Science<\/a> about anti-CD3 monoclonal antibodies (currently best known as teplizumab) and Type 1 diabetes was just featured on the New Hampshire Public Radio show Word of Mouth. <\/em>(You can read about the segment, and listen to the interview, here.)<\/p>\n

It’s always great to get to talk about something you’ve worked hard on, but I found myself getting surprisingly nervous before this particular interview. Part of it was my typical worry that I am somehow going to lose my ability to speak English the moment the host asks me a question. (Words? What are words?) But this time, there was an added challenge: talking intelligently about immunology — an area in which I am not an expert — about a complicated subject in a way that the general public could understand. (You guys will have to let me know how I did!) Luckily, words did indeed come out of my mouth, and by the end of the segment, \u00a0I was actually enjoying myself. But it’s interesting to feel your body pumping up the adrenaline — and I have a feeling that may have had something to do with the fact that my blood sugar went high this morning and has only now come back down.<\/p>\n

And that’s very good news: it’s 2:15 in the afternoon, and I haven’t eaten lunch.<\/p>\n","protected":false},"excerpt":{"rendered":"

…<\/p>\n","protected":false},"author":9,"featured_media":53098,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1501],"tags":[660],"yoast_head":"\nTeplizumab on New Hampshire Public Radio's Word of Mouth<\/title>\n<meta name=\"description\" content=\"An interview on NHPR about teplizumab, an anti-cd3 monoclonal antibody developed by Jeff Bluestone at UCSF that's being tested in people with newly diagnosed Type 1 diabetes and other autoimmune diseases like ulcerative colitis and psoriasis. Originally published in Popular Science\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=5823\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Catherine Price\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=5823\",\"url\":\"https:\/\/asweetlife.org\/?p=5823\",\"name\":\"Teplizumab on New Hampshire Public Radio's Word of Mouth\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=5823#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=5823#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2021\/01\/ASL-Social-Big-Square-3.jpg\",\"datePublished\":\"2010-03-10T22:18:15+00:00\",\"dateModified\":\"2015-12-27T20:44:29+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/f16ebb52b0d6b1882336149c48618b74\"},\"description\":\"An interview on NHPR about teplizumab, an anti-cd3 monoclonal antibody developed by Jeff Bluestone at UCSF that's being tested in people with newly diagnosed Type 1 diabetes and other autoimmune diseases like ulcerative colitis and psoriasis. Originally published in Popular Science\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=5823#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=5823\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=5823#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2021\/01\/ASL-Social-Big-Square-3.jpg\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2021\/01\/ASL-Social-Big-Square-3.jpg\",\"width\":1280,\"height\":1280},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=5823#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teplizumab on Word of Mouth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/f16ebb52b0d6b1882336149c48618b74\",\"name\":\"Catherine Price\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/991f86d105bb54022be9be587aa788fa?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/991f86d105bb54022be9be587aa788fa?s=96&d=mm&r=g\",\"caption\":\"Catherine Price\"},\"description\":\"Catherine Price was diagnosed with Type 1 diabetes when she was 22 years old. She has written for publications including The Best American Science Catherine Price is a professional journalist who was diagnosed with Type 1 diabetes when she was 22 years old. Her work has been featured in publications including The Best American Science Writing, The New York Times, Popular Science, The Los Angeles Times, The San Francisco Chronicle, The Washington Post Magazine, Salon, Slate, Men\u2019s Journal, Health Magazine, The Oprah Magazine, and Outside, among others. A graduate of Yale and UC Berkeley\u2019s Graduate School of Journalism\",\"url\":\"https:\/\/asweetlife.org\/?author=9\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Teplizumab on New Hampshire Public Radio's Word of Mouth","description":"An interview on NHPR about teplizumab, an anti-cd3 monoclonal antibody developed by Jeff Bluestone at UCSF that's being tested in people with newly diagnosed Type 1 diabetes and other autoimmune diseases like ulcerative colitis and psoriasis. Originally published in Popular Science","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=5823","twitter_misc":{"Written by":"Catherine Price","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=5823","url":"https:\/\/asweetlife.org\/?p=5823","name":"Teplizumab on New Hampshire Public Radio's Word of Mouth","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=5823#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=5823#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2021\/01\/ASL-Social-Big-Square-3.jpg","datePublished":"2010-03-10T22:18:15+00:00","dateModified":"2015-12-27T20:44:29+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/f16ebb52b0d6b1882336149c48618b74"},"description":"An interview on NHPR about teplizumab, an anti-cd3 monoclonal antibody developed by Jeff Bluestone at UCSF that's being tested in people with newly diagnosed Type 1 diabetes and other autoimmune diseases like ulcerative colitis and psoriasis. Originally published in Popular Science","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=5823#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=5823"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=5823#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2021\/01\/ASL-Social-Big-Square-3.jpg","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2021\/01\/ASL-Social-Big-Square-3.jpg","width":1280,"height":1280},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=5823#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Teplizumab on Word of Mouth"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/f16ebb52b0d6b1882336149c48618b74","name":"Catherine Price","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/991f86d105bb54022be9be587aa788fa?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/991f86d105bb54022be9be587aa788fa?s=96&d=mm&r=g","caption":"Catherine Price"},"description":"Catherine Price was diagnosed with Type 1 diabetes when she was 22 years old. She has written for publications including The Best American Science Catherine Price is a professional journalist who was diagnosed with Type 1 diabetes when she was 22 years old. Her work has been featured in publications including The Best American Science Writing, The New York Times, Popular Science, The Los Angeles Times, The San Francisco Chronicle, The Washington Post Magazine, Salon, Slate, Men\u2019s Journal, Health Magazine, The Oprah Magazine, and Outside, among others. A graduate of Yale and UC Berkeley\u2019s Graduate School of Journalism","url":"https:\/\/asweetlife.org\/?author=9"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/5823"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5823"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/5823\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/53098"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5823"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}